RxDoctor Payments Data

Faafouina Afato, MD

Family Medicine · Yuba City, CANPI 1023075348

Payments from drug & device makers

$11,964in general payments, 2019–2025

Across 688 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$2K
  • Boehringer Ingelheim$1K
  • GSK$953
  • Novo Nordisk$632
  • Pfizer$574
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$11,922100%
  • Education$420%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,964 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$340,548
Medicare patients
597
Services billed
4,046

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin100$82,729
OzempicSemaglutide67$61,791
FarxigaDapagliflozin Propanediol85$59,159
EliquisApixaban75$56,470
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$52,684
TrulicityDulaglutide43$40,172
JanuviaSitagliptin Phosphate26$30,789
Soliqua 100-33Insulin Glargine/Lixisenatide19$15,577
Bydureon BciseExenatide Microspheres16$13,096
DapagliflozinDapagliflozin Propanediol19$10,091
LinzessLinaclotide17$9,528
Tresiba Flextouch U-100Insulin Degludec13$8,492
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,041
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$7,715
NamzaricMemantine Hcl/Donepezil Hcl12$6,969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$1,043$95,792124 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,527$65,91596 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$953$64,922110 claims
Novo NordiskOzempic$632$61,79167 claims
PfizerEliquis$574$56,47075 claims
Lilly USA, LLCTrulicity$518$40,17243 claims
MerckJanuvia$184$30,78926 claims
AbbVieLinzess, Namzaric$3,021$16,49729 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$312$15,57719 claims
Redhill Biopharma Inc.Movantik$36$6,09815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Yuba City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →